Biotech · Private company
Albireo, an Ipsen Company
Track this companyFree. Adds Albireo, an Ipsen Company to your Dealase workspace and tells you when its record changes.
Clinical trials42 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline3
- A4250 (odevixibat)Phase 3 · Progressive Familial Intrahepatic CholestasisClinicalTrials.gov · fetched Nov 12, 2026
- OdevixibatPhase 3 · Alagille SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- OdevixibatPhase 3 · Biliary AtresiaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary AtresiaPHASE3 · ACTIVE_NOT_RECRUITING · started Jul 5, 2022ClinicalTrials.gov NCT05426733 · fetched Nov 12, 2026
- Long-term Safety and Efficacy of Odevixibat in Patients With Alagille SyndromePHASE3 · ACTIVE_NOT_RECRUITING · started Sep 3, 2021ClinicalTrials.gov NCT05035030 · fetched Nov 12, 2026
- Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)PHASE3 · COMPLETED · started Jul 8, 2020ClinicalTrials.gov NCT04336722 · fetched Nov 12, 2026
- Long Term Safety & Efficacy Study Evaluating The Effect of A4250 in Children With PFICPHASE3 · COMPLETED · started Sep 28, 2018ClinicalTrials.gov NCT03659916 · fetched Nov 12, 2026